22132 Overcoming the Challenges of Acute and Chronic GVHD: Learning Workshop on the Integration of Novel Therapies into Modern Management Protocols

Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management.

This activity can be accessed using the following URL: www.peerview.com/KPJ

This activity is supported through educational grants from Bristol Meyers Squibb.

 

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients with GVHD.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others
  • Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD
  • Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management
Additional information

Contact

Name: 
Mallory Ahern
Phone Number: 
+1 (914) 737-6528
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
05/19/2022
Course expires: 
05/20/2023
Cost:
$0.00

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair & Presenter
Leslie Kean, MD, PhD
Stranahan Professor of Pediatrics
Harvard Medical School
Director, Stem Cell Transplantation Program
Division of Pediatric Hematology/Oncology
Boston Children's Hospital
Department of Pediatric Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Leslie Kean, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for EMD Serono, Inc.; Equillium, Inc.; Forty Seven, Inc.; Gilead Sciences, Inc.; HiFiBiO Therapeutics; Mammoth Biosciences, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from bluebird bio, Inc.; Bristol Myers Squibb; Kymab; Magenta Therapeutics; and Regeneron Pharmaceuticals Inc.

Presenters
Corey Cutler, MD, MPH, FRCP(C)
Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey Cutler, MD, MPH, FRCP(C), has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; CareDx, Inc.; Cimeio Therapeutics AG; CTI BioPharma Corp.; Deciphera Pharmaceuticals, Inc.; Editas Medicine; Equillium, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mallinckrodt Pharmaceuticals; Omeros Corporation; Pfizer; and Sanofi US.

Shernan Holtan, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Transplantation
University of Minnesota
Minneapolis, Minnesota

Shernan Holtan, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Incyte Corporation and VITRAC Therapeutics, LLC.
Other Financial or Material Support from CSL Behring as the clinical trial adjudicator.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.